Safety and efficacy of the treatment with the beecura beehive air therapy system BCS-IH16

Safety and efficacy of the treatment with the beecura beehive air therapy system BCS-IH16 - swarm study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

DRKS

Registry ID

DRKS00012661

Enrollment

Registered

2018-04-30

Start date

2018-05-03

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

J44 J45

Interventions

Group 1: Patients with COPD or Asthma bronchiale and a FEV1 between 50 and 80%. Patients inhale beehive air using the beecura beehive air therapy system BCS-IH16 (10 daily therapy sessions over 10 day

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - patients must be capable to fill out an questionnaire on their quality of life - patients with a COPD or Asthma bronchiale and FEV1 between 50 % and 80 % - stable pulmonary medication without any changes in the last seven days - written informed consent

Exclusion criteria

Exclusion criteria: - acute exacerbation of the pulmonary disease - allergy against bee or wasp stings - restrictive lung disorders - malignant disease which is not yet cured - diseases with a life expectancy less than 6 months - heart insufficiency with an ejection fraction of less than 40 % - imprisoned individuals or mental immature adults - pregnant or breastfeeding patients - women of child bearing potential not using contraception - drug and alcohol abuse - patients not capable of giving consent - severe cognitive deficits or dementia - participation in other clinical studies - persons who may be dependet on the sponsor or investigator

Design outcomes

Primary

Measure	Time frame
Efficacy, measured by FEV1 (%). The efficacy is considered as verified when the FEV1 has improved by 6 % after the inhalation of the beehive air. Measuring time points: before study start and after beehive air therapy. The efficacy will be measured by a questionnaire (SF-36) and evaluation by the patient.	—

Secondary

Measure	Time frame
Safety, measured by: 1) occurences of allergic reactions or anaphylactic shock during or immediately after inhalation of the beehive air 2) dyspnoea during the inhalation of the beehive air or deterioration of FEV1 immediately after the beehive air inhalation.	—

Countries

Germany

Contacts

Public ContactThomas Huber

Praxis

drhuberthomas@googlemail.com03772 381901

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026